6.38  -1.1 (-14.71%)		03-12 16:00
Open: 7.115 High: 7.23 Volume: 33,143		Pre. Close: 7.48 Low: 6.355 Market Cap: 26(M)

Short term
Mid term
Targets	6-month :	13.89	1-year :	17.98
Resists	First :	11.89	Second :	15.39
Pivot price	10.82
Supports	First :	6.21	Second :	5.17
MAs	MA(5) :	7.34	MA(20) :	11.59
	MA(100) :	19.09	MA(250) :	38.9
MACD	MACD :	-2.2	Signal :	-1.7
%K %D	K(14,3) :	10.9	D(3) :	13.9
RSI	RSI(14): 20.8
52-week	High :	75.5	Low :	6.21

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TVGN ] has closed above bottom band by 13.5%. Bollinger Bands are 79.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	7.23 - 7.28	7.28 - 7.32
Low:	6.27 - 6.31	6.31 - 6.35
Close:	6.32 - 6.39	6.39 - 6.44

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Wed, 11 Mar 2026
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform - Bitget

Wed, 11 Mar 2026
Tevogen Bio Accelerates Development of TVGN 489 for Long COVID with New Leadership and Strategic Initiatives - Quiver Quantitative

Mon, 09 Mar 2026
Tevogen Bio Holdings Inc. Appoints Interim Leaders to Drive Diversified Growth Strategy - Quiver Quantitative

Mon, 09 Mar 2026
Inside Tevogen's $50M expansion push and the team picked to run it - Stock Titan

Fri, 06 Mar 2026
Tevogen Bio explores acquisitions that may add $50M+ in yearly revenue - Stock Titan

Fri, 06 Mar 2026
Tevogen Bio Explores Buyout To Boost Generics Platform - Benzinga

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	4 (M)
Shares Float	1 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	60 (K)
Shares Short P.Month	53 (K)

EPS	-9
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-4.22
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-439.7 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-7.59
Qtrly Earnings Growth	0 %
Operating Cash Flow	-13 (M)
Levered Free Cash Flow	-1 (M)

PE Ratio	-0.71
PEG Ratio	0
Price to Book value	-1.52
Price to Sales	0
Price to Cash Flow	-1.96

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.